Aktie A2QPL7 NOCTURNE ACQUISITION CORPORATION
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Nocturne Acquisition Corporation

Aktien

A2QPL7

KYG6580S1140

MBTC

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:00:00 03.04.2024 		% 5 Tage % 1. Jan.
11,66 USD -0,49 % Intraday Chart für Nocturne Acquisition Corporation -.--% +0,08 %
31.03. Cognos Therapeutics Inc. hat die Übernahme von Nocturne Acquisition Corporation (NasdaqCM:MBTC) von einer Gruppe von Aktionären in einer Reverse-Merger-Transaktion abgesagt. CI
07.02. Nocturne Acquisition Corporation kündigt Änderungen im Management an CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Nocturne Acquisition Corporation(NasdaqCM:MBTC) dropped from NASDAQ Composite Index
Cognos Therapeutics Inc. cancelled the acquisition of Nocturne Acquisition Corporation from a group of shareholders in a reverse merger transaction.
Nocturne Acquisition Corporation Announces Management Changes
Sector Update: Financial Stocks Ease Late Afternoon
Sector Update: Financial
Nocturne Acquisition Shares Jump as Stockholders' Vote on Merger With Cognos Therapeutics Postponed Further
Nocturne Acquisition Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Chardan Engaged to Facilitate Nocturne Acquisition Corporation's Business Combination with Cognos Therapeutics, Inc., Paving the Way for NASDAQ Listing
Nocturne Acquisition Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Nocturne Acquisition Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023
Nocturne Acquisition Corporation Reports Earnings Results for the Full Year Ended December 31, 2022
Nocturne Acquisition Corporation Auditor Raises 'Going Concern' Doubt
NOCTURNE ACQUISITION CORP : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)
NOCTURNE ACQUISITION CORP : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
NOCTURNE ACQUISITION CORP : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
NOCTURNE ACQUISITION CORP : Regulation FD Disclosure (form 8-K)
NOCTURNE ACQUISITION CORP : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
NOCTURNE ACQUISITION CORP : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
Nocturne Acquisition in Deal to Merge With Cognos Therapeutics
Cognos Therapeutics Inc. executed a definitive business combination agreement to acquire Nocturne Acquisition Corporation from Nocturne Sponsor, LLC, Polar Asset Management Partners Inc., Periscope Capital Inc, Sea Otter Advisors LLC and others for approximately $120 million in a reverse merger transaction.
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2QPL7 Aktie
  4. Nachrichten Nocturne Acquisition Corporation
  5. Andere Sprachen